Search
Apremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalApremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesLumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigationalSchizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including aripiprazole, paliperidone and clozapine available for clinical use, they are generally accompa...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMianserin
go.drugbank.com/drugs/DB06148ApprovedWithdrawnA tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnNylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impair...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGarenoxacin
go.drugbank.com/drugs/DB06160ExperimentalGarenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTolperisone
go.drugbank.com/drugs/DB06264InvestigationalTolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMitemcinal
go.drugbank.com/drugs/DB06587InvestigationalMitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsVicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was develop...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesVilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight ga...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsLaquinimod
go.drugbank.com/drugs/DB06685InvestigationalLaquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates